PIN-2 is under clinical development by PIN Pharma and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how PIN-2’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
PIN-2 is under development for the treatment of triple negative breast cancer, and metastatic lung cancer. The drug candidate is derived from a trans-activator of transcription polypeptide. It is administered by intravenous route.
PIN Pharma overview
PIN Pharma that focused on developing broad-base immuno-modulatory therapies, using an innovative approach to link the innate and adaptive immune systems. The company is headquartered in New York city, New York, the US.
For a complete picture of PIN-2’s drug-specific PTSR and LoA scores, buy the report here.